Literature DB >> 17069350

Diminished macrophage cholesterol removal rate by the altered HDL metabolism in the Nagase analbuminemic rat.

Sergio Catanozi1, Jussara C Rocha, Marisa Passarelli, Carlos H Mesquita, Vivian Y Suguiama, Maria L Guzzo, Antônio dos Santos Filho, Eder C R Quintão, Edna R Nakandakare.   

Abstract

Dyslipoproteinemia of the Nagase analbuminemic rat (NAR) is characterized by elevated concentrations of VLDL and LDL attributed to increased rates of liver lipoprotein synthesis. Increased lysophosphatidylcholine (LPC) in NAR HDL has been attributed to high plasma LCAT activity. We show here that, as compared with Sprague-Dawley rats (SDR), NAR plasma triacylglycerol (TAG), total cholesterol (TC), HDL TAG, protein, total phospholipids (PL), LPC, and PS are increased. These alterations rendered the NAR HDL particle more susceptible to the activity of the enzyme hepatic lipoprotein lipase (HL), which otherwise was unaltered in our study. Fractional catabolic rates in blood of the autologous 125I-apoHDL (median and lower quartile values), were, respectively, 0.231 and 1.645 (n = 10) in NAR as compared with 0.140 and 0.109 (n = 10) in SDR (P = 0.012), corresponding to synthesis rates of HDL protein of 89.8 +/- 33.7 mg/d in NAR and 17.4 +/- 6.5 mg/d in SDR (P = 0.0122). Furthermore, Swiss mouse macrophage free-cholesterol (FC) efflux rates, measured as the percent [14C]-cholesterol efflux/6 h, were 8.2 +/- 2.3 (n = 9) in NAR HDL and 11.2 +/- 3.2 (n = 10) in SDR HDL (P = 0.03). Therefore, in NAR the modification of the HDL composition slows down the cell FC efflux rate, and together with the increased rate of plasma HDL metabolism influences the reverse cholesterol transport system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17069350     DOI: 10.1007/s11745-006-5017-6

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  51 in total

1.  Diminished rate of mouse peritoneal macrophage cholesterol efflux is not related to the degree of HDL glycation in diabetes mellitus.

Authors:  M Passarelli; A F Shimabukuro; S Catanozi; E R Nakandakare; J C Rocha; A J Carrilho; E C Quintão
Journal:  Clin Chim Acta       Date:  2000-11       Impact factor: 3.786

2.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

3.  Clearance of postprandial and lipolytically modified human HDL in rabbits and rats.

Authors:  G F Lewis; B Lamarche; K D Uffelman; A C Heatherington; M A Honig; L W Szeto; P H Barrett
Journal:  J Lipid Res       Date:  1997-09       Impact factor: 5.922

4.  Separation of plasma lipoproteins by density-gradient ultracentrifugation.

Authors:  T G Redgrave; D C Roberts; C E West
Journal:  Anal Biochem       Date:  1975-05-12       Impact factor: 3.365

Review 5.  Fatty acid binding to plasma albumin.

Authors:  A A Spector
Journal:  J Lipid Res       Date:  1975-05       Impact factor: 5.922

Review 6.  Genetics and molecular biology of hepatic lipase.

Authors:  A Bensadoun; D E Berryman
Journal:  Curr Opin Lipidol       Date:  1996-04       Impact factor: 4.776

7.  Albumin restores lysophosphatidylcholine-induced inhibition of vasodilation in rat aorta.

Authors:  T D Vuong; S de Kimpe; R de Roos; T J Rabelink; H A Koomans; J A Joles
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

Review 8.  New insights into lipid metabolism in the nephrotic syndrome.

Authors:  G A Kaysen; M G de Sain-van der Velden
Journal:  Kidney Int Suppl       Date:  1999-07       Impact factor: 10.545

Review 9.  The role of the kidney in lipid metabolism.

Authors:  Søren K Moestrup; Lars Bo Nielsen
Journal:  Curr Opin Lipidol       Date:  2005-06       Impact factor: 4.776

10.  Plasma triglyceride levels are higher in nephrotic than in analbuminemic rats despite a similar increase in hepatic triglyceride secretion.

Authors:  J A Joles; C Bijleveld; A van Tol; M J Geelen; H A Koomans
Journal:  Kidney Int       Date:  1995-02       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.